Cantor Fitzgerald reiterated their overweight rating on shares of Kura Oncology (NASDAQ:KURA – Get Rating) in a research report report published on Wednesday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Kura Oncology’s FY2022 earnings at ($2.21) EPS and FY2023 earnings at ($2.63) EPS.
KURA has been the topic of several other reports. Credit Suisse Group lifted their target price on Kura Oncology from $27.00 to $29.00 and gave the company an outperform rating in a research report on Wednesday, July 13th. Wedbush reissued an outperform rating and set a $40.00 price target on shares of Kura Oncology in a report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology currently has a consensus rating of Moderate Buy and a consensus target price of $37.50.
Kura Oncology Trading Up 4.2 %
Shares of KURA opened at $12.51 on Wednesday. The company has a market cap of $836.79 million, a price-to-earnings ratio of -6.26 and a beta of 0.93. Kura Oncology has a 12 month low of $10.41 and a 12 month high of $21.10. The business’s fifty day simple moving average is $15.13 and its two-hundred day simple moving average is $15.17.
Institutional Investors Weigh In On Kura Oncology
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC increased its holdings in shares of Kura Oncology by 9.1% in the second quarter. Verition Fund Management LLC now owns 538,087 shares of the company’s stock worth $9,863,000 after purchasing an additional 44,949 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Kura Oncology by 6.4% in the second quarter. Legal & General Group Plc now owns 20,467 shares of the company’s stock worth $376,000 after purchasing an additional 1,225 shares during the last quarter. ExodusPoint Capital Management LP increased its holdings in shares of Kura Oncology by 178.5% in the second quarter. ExodusPoint Capital Management LP now owns 52,330 shares of the company’s stock worth $959,000 after purchasing an additional 33,540 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Kura Oncology by 100.5% in the second quarter. Goldman Sachs Group Inc. now owns 965,026 shares of the company’s stock worth $17,689,000 after purchasing an additional 483,836 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Kura Oncology by 78.4% in the second quarter. Jane Street Group LLC now owns 18,333 shares of the company’s stock worth $336,000 after purchasing an additional 8,057 shares during the last quarter.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
- Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.